Clinical Design and Key Hypothesis

The G-SUMIT trial, led by Sunnybrook Research Institute and supported by the Canadian Institutes of Health Research, is a multi-center, randomized Phase 2 pilot study involving 72 newly diagnosed high-grade glioma patients. The intervention group undergoes maximal resection extending up to 1cm beyond the 95% gadolinium-enhancing boundary or to adjacent sulci and ventricular walls, while the control group receives standard complete resection within the contrast-enhancing area. The study is based on pathological evidence that 80% of tumors recur within 1–2cm of the initial lesion, with infiltrating cells potentially extending 6–14mm beyond MRI-defined boundaries. The immediate objective is to validate patient recruitment, treatment compliance, and surgical safety prior to a large-scale confirmatory trial.

Efficacy and Neurological Safety

The trial tracks overall survival (OS), progression-free survival (PFS), neurological deterioration within 30 days post-surgery, quality of life, and resection extent. While extended resection may reduce residual infiltrating cells, it carries a higher risk of permanent functional deficits if motor, language, or cognitive areas are involved. Therefore, balancing maximal resection with functional preservation is critical. The study also evaluates whether the radiological resection rate correlates with actual survival benefits at 6 weeks, 6 months, and 12 months post-surgery. As such, the results should be interpreted as a surgical clinical trial, where outcomes are significantly influenced by surgeon selection, anatomical location, and functional mapping rather than drug response.

Standard of Care and Competitive Technologies

The current standard of care for newly diagnosed glioblastoma includes maximal safe resection followed by radiotherapy and temozolomide (a DNA alkylating agent), with maintenance therapy. Novocure (NVCR)'s Optune Gio (tumor-treating electric fields that disrupt mitosis) was approved by the FDA in October 2015 for use in combination with temozolomide. For recurrent patients, bevacizumab (VEGF-A target), lomustine, and carmustine are also used. Surgical alternatives include 5-ALA fluorescence guidance, intraoperative MRI, neuro-navigation, awake surgery, and functional mapping. G-SUMIT aims to utilize these adjunctive technologies to enable a safe 1cm extended resection, rather than replacing them.

Market and Industry Implications

The global glioblastoma treatment market is estimated at USD 4.0 billion in 2025 and is projected to reach USD 7.9 billion by 2033. If extended resection improves both survival and functional preservation, it could first impact the demand for intraoperative imaging, fluorescent diagnostics, ultrasound, neuromonitoring, and precision navigation systems, rather than new drug sales. However, a pilot study of 72 patients alone is insufficient to establish a change in standard care; a well-powered confirmatory randomized trial with sufficient statistical power is necessary, based on recruitment feasibility and safety signals. No financial transactions or licensing agreements are involved, and the study is funded by Canadian public research grants.